As filed with the Securities and Exchange Commission on February 15, 2001
Registration No. 333-
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
-------------------
INFINITE GROUP, INC.
----------------------------------
(Exact name of Registrant as
specified in its charter)
Delaware 3690 52-1490422
- --------------------- ---------------------------------- ------------------
(State or other (Primary Standard Industrial (I.R.S. Employer
jurisdiction of Classification Code Identification No.)
incorporation or Number)
organization)
----------------------------
2364 Post Road
Warwick, RI 02886
(401) 738-5777
----------------------------------------
(Address, including zip code, and
telephone number, including area code,
of Registrant's executive offices)
----------------------------
Clifford G. Brockmyre, II, CEO
2364 Post Road
Warwick, RI 02886
(401) 738-5777
----------------------------------------
(Name, address, including zip code,
and telephone number, including area
code, of agent for service)
--------------------------
Copies to:
Kenneth S. Rose, Esq.
Morse, Zelnick, Rose & Lander, LLP
450 Park Avenue
New York, New York 10022
(212) 838-5030
-------------------------------------------
Approximate date of commencement of proposed sale to the public: As soon
as practicable after this Registration Statement becomes effective.
If the only securities being registered on this Form are to be offered
pursuant to dividend or reinvestment plans, please check the following box. |_|
If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, as amended (the "Securities Act") other than securities offered only in
connection with dividend or reinvestment plans, check the following box. |X|
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration
statement for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration
statement for the same offering. |_|
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. |_|
-----------------------
CALCULATION OF REGISTRATION FEE
================================================================================
Proposed
Title of Each Class Amount Maximum Proposed Maximum Amount of
of Securities to be to be Offering Aggregate Offering Registration
Registered Registered Price(1) Price(1) Fee
- --------------------------------------------------------------------------------
Common stock,
$0.001 par value
per share..........442,200(2) $3.00 (3) $1,326,600.00 $331.65
- --------------------------------------------------------------------------------
Common stock,
$0.001 par value
per share
underlying
warrants........... 4,300 $3.95 (4) $ 16,986.00 $ 4.25
- --------------------------------------------------------------------------------
Total................446,500 $1,343,586.00 $335.90
================================================================================
- -------------------
(1) The proposed maximum offering price is estimated solely for the purposes
of calculating the registration fee pursuant to Rule 457(c) and 457(g)(3)
of the Securities Act of 1933.
(2) Includes 150,000 shares of common stock to be issued upon exercise of
common stock purchase warrants.
(3) The last reported sales price of the registrant's common stock as reported
on the Nasdaq SmallCap Market System on February 14, 2001.
(4) The exercise price of the warrants.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE
SECURITIES ACT OF 1933 OR UNTIL THIS REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
================================================================================
The information in this prospectus is not complete and may be changed.
These securities may not be sold until the registration statement of which this
prospectus is a part filed with the Securities and Exchange Commission is
declared effective. This prospectus is not an offer to sell these securities and
it is not soliciting an offer to buy these securities in any state where the
offer or sale is not permitted.
PROSPECTUS
SUBJECT TO COMPLETION
DATED FEBRUARY 15, 2001
446,500 Shares
Common Stock
INFINITE GROUP, INC.
[LOGO]
The selling stockholders identified in this prospectus are offering to
sell up to 446,500 shares of our common stock. Of this amount, 154,300 shares
are covered by warrants held by selling stockholders that have not yet been
exercised and 31,250 shares are issuable to a selling stockholder on May 26,
2001.
We will not receive any of the proceeds from the sale of these shares. The
shares are being registered for resale by the selling stockholders.
Our common stock is quoted on the Nasdaq SmallCap Market under the symbol
"IMCI." The last reported sale price of our common stock on the Nasdaq SmallCap
Market on ____________, 2001 was $_________ per share.
Investing in our common stock involves a high degree of risk. See "Risk
Factors" beginning on page 11.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is accurate or complete. Any representation to the contrary is a
criminal offense.
The date of this prospectus is _________________, 2001
TABLE OF CONTENTS
Page
Where You Can Find More Information..........................................3
Reports to Security Holders..................................................3
Incorporation of Certain Documents by Reference..............................3
Special Note Regarding Forward-Looking Statements............................4
The Company..................................................................5
Risk Factors................................................................11
Use of Proceeds.............................................................18
Selling Stockholders........................................................19
Plan of Distribution........................................................20
Legal Matters...............................................................21
Experts.....................................................................21
----------------------------
You should rely only on the information contained or incorporated by
reference in this prospectus. We have not authorized anyone to provide you with
any other information. We are not making an offer of these securities in any
state where the offer is not permitted. You should not assume that the
information in this prospectus is accurate as of any date other than the date on
the front cover.
References in this prospectus, and the documents incorporated by reference
in this prospectus, to "Infinite," "we," "our," and "us" refer to Infinite
Group, Inc., a Delaware corporation. We maintain web sites at
www.infinite-group.com, www.laserfare.com, www.infinitephotonics.com,
www.expresspattern.com and www.expresstool.com. None of the information
contained in any of our web sites constitute part of this prospectus.
We own various intellectual property rights to our name and the names of
our subsidiaries, as well as the Infinite Group logo. This prospectus also
contains trademarks and tradenames belonging to other persons.
WHERE YOU CAN FIND MORE INFORMATION
We are required to comply with the informational and reporting
requirements of the Securities Exchange Act of 1934, as amended. As required by
that statute, we have filed various reports, proxy statements and other
information with the Securities and Exchange Commission. You may inspect these
reports, proxy statements and other information at the public reference
facilities of the Securities and Exchange Commission at its principal offices at
Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, and
at its regional offices located at 500 West Madison Street, Suite 1400, Chicago,
Illinois 60661-2511, and 7 World Trade Center, Suite 1300, New York, New York
10048. You can get copies of these reports, proxy statements and other
information from these offices by paying the required fees. Please call the
Securities and Exchange Commission at (800) SEC-0330 for further information
regarding the operation of its public reference room. These reports, proxy
statements and other information can also be accessed over the Internet at the
web site maintained by the Securities and Exchange Commission at
http://www.sec.gov.
We have filed a registration statement on Form S-3 with the Securities and
Exchange Commission under the Securities Act regarding the shares of our common
stock covered by this prospectus. This prospectus, which forms a part of that
registration statement, does not contain all of the information included in that
registration statement and its accompanying exhibits. Statements contained in
this prospectus regarding the contents of any document are not necessarily
complete and are qualified in their entirety by that reference. You should refer
to the actual document as filed with the Securities and Exchange Commission.
REPORTS TO SECURITY HOLDERS
We furnish our stockholders with annual reports containing audited
financial statements. In addition, we are required to file reports on Forms
8-KSB, 10-QSB and 10-KSB with the Securities and Exchange Commission.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by us with the Securities and Exchange
Commission are incorporated in this prospectus by reference:
(1) Annual Report on Form 10-KSB for the fiscal year ended December 31,
1999;
(2) Quarterly Report on Form 10-QSB for the quarters ended March 31,
June 30 and September 30, 2000;
(3) Current Report on Form 8-K, dated January 10, 2001;
(4) Definitive proxy statement dated February __, 2001; and
(5) Registration Statement on Form 8-A, filed September 23, 1993.
Each document filed after the date of this prospectus under Section 13(a),
13(c), 14 or 15(d) of the Securities Exchange Act but before this offering
terminates is incorporated in this prospectus by reference and is to be treated
as part of this prospectus as of the date it is filed. Any statement contained
in a document incorporated or deemed to be incorporated in this prospectus by
reference is modified or superseded to the extent that a statement contained in
this prospectus or in any other subsequently filed document that is incorporated
in this prospectus by reference modifies or supersedes that statement.
We will provide, without charge, each person to whom a copy of this
prospectus is delivered, a copy of any document incorporated by reference in
this prospectus (other than exhibits, unless those exhibits are specifically
incorporated by reference in those documents) if it is requested. Requests
should
3
be directed to Infinite Group, Inc., 2364 Post Road, Warwick, Rhode island
02886, Attention: Clifford G. Brockmyre II, President and Chief Executive
Officer.
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATIONS IN CONNECTION WITH THIS OFFERING OTHER THAN THOSE CONTAINED IN
THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH OTHER INFORMATION AND
REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY US. NEITHER
THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE OF SHARES OF OUR COMMON STOCK
COVERED BY THIS PROSPECTUS SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY
IMPLICATION THAT THERE HAS BEEN NO CHANGE IN OUR AFFAIRS SINCE THE DATE OF THIS
PROSPECTUS OR THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME
SUBSEQUENT TO ITS DATE. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR
A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OTHER THAN THE REGISTERED
SECURITIES TO WHICH IT RELATES. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY CIRCUMSTANCES IN
WHICH THE OFFER OR SOLICITATION IS UNLAWFUL.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference in this
prospectus contain forward-looking statements that involve substantial risks and
uncertainties. You can identify these statements by forward-looking words such
as "anticipate," "believe," "could," "estimate," "expect," "intend," "may,"
"should," "will" and "would" or similar words. You should read statements that
contain these words carefully because they discuss our future expectations,
contain projections of our future results of operations or of our financial
position or state other "forward-looking" information. We believe that it is
important to communicate our future expectations to our stockholders. However,
there may be events in the future that we are not able to accurately predict or
control. The factors listed below in the section captioned "Risk Factors," as
well as any cautionary language in this prospectus, provide examples of risks,
uncertainties and events that may cause our actual results to differ materially
from the expectations we describe in our forward-looking statements. Before you
invest in our common stock, you should be aware that the occurrence of the
events described in these risk factors and elsewhere in this prospectus could
have a material adverse effect on our business, results of operations, financial
position and the price of our common stock.
4
THE COMPANY
Our business has two segments, the Laser and Photonics Group and the
Plastics Group. We sell products and services in the fields of material
processing, advanced manufacturing methods, high productivity production mold
building and laser-application technology. Our Laser and Photonics Group
provides comprehensive laser-based materials and processing services. Our
Plastics Group provides rapid prototyping services and proprietary mold building
services.
The Laser and Photonics Group
We are a leading provider of applied photonics. Specifically, we provide
high value, laser-based manufacturing services to industrial customers. We use
laser driven technologies that enable cost effective component fabrication for
customers in the aerospace, defense, medical, telecommunications and sensing
industries. Through industry and government funded research, we have developed
proprietary manufacturing techniques that, we believe, have established us as a
valued supplier of engineered components. These skill sets range from classical
laser materials processing to state of the art injection molding tooling
technology.
Photonics is the science of generating and harnessing light to do useful
work. Lasers and fiber optics are the best known expressions of photonics
technology. According to Lucent Technologies' Vision Statement: "Optical
technology will be as important to the 21st Century as electricity was to the
20th Century."
Photonic technologies use light to:
o deposit materials;
o detect, transmit, store and process information;
o generate energy; and
o capture and display images.
The basic unit of light is the photon, while in electronics it is the
electron. Because photons are massless and travel faster than electrons,
photonic devices can be smaller and significantly faster than electronic
devices. For example, replacing electronics (copper wire) with photonics (fiber
optic cable) boosts the capacity of telecommunications transmission lines by a
factor of 10,000.
Photonic components are the "enabling technology" in many familiar
consumer products including CD-ROM players, digital cameras, displays on laptop
computers and calculators, fiber optic cable for telephones, cable television,
and networked computer systems. In industry, photonics "eyes" enable robots to
"see." Photonics is also found in semiconductor manufacturing as well as
analytical and process-monitoring applications. In medicine, photonics is at the
core of diagnostic instrumentation, laser microsurgery, and filmless real-time
imaging.
Our Evolution in Applied Photonics
Since their invention in the early 1960's, lasers have played an
increasingly important role in manufacturing through processes including
welding, cutting, drilling, and engraving. Laser Fare, one of our subsidiaries,
was formed in 1978 to provide these services and has established itself as a
leading provider in that area. One of our founders was the immediate past
president of the Laser Institute of America, a not-for-profit trade group
representing the photonics industry.
5
In the last several years improvements in laser performance and new
adaptations of their use have enabled the development of a number of new
manufacturing processes. These processes not only provide significant
improvements over older generation laser processes, but permit the manufacture
of products that previously could not be produced on a cost-effective basis.
Through our Laser Fare Advanced Technology Group ("ATG"), the research and
development unit within Laser Fare, we have played a key role in developing
several laser processes and, as a result, have developed a portfolio of
intellectual property rights. We are focusing our future business development
efforts and our future growth in these new areas.
Our Strategic Alliance Partners and Consortia
As a result of our expertise in the field of applied photonics, we have
established strategic alliances with a number of private sector companies,
academic institutions and public/private consortia. For example, our expertise
in the area of direct write and grating coupled surface emitting lasers
("GCSEL") has made possible our alliances with Cutting Edge Optronics, Inc.,
Triton Systems Inc. and the University of Connecticut. We are also a member of
the LENS(R) CRADA (Laser Engineered Net Shaping -- Cooperative Research and
Development Agreement) at Sandia National Laboratories. Other members of LENS(R)
CRADA include Ford Motor, Motorola, Lockheed Martin, and others. In addition, we
serve on three DARPA MICE (Defense Advanced Research Projects Agency -Mesoscopic
Integrated Conformal Electronics) teams along with Optomec, CMS Technetronics
and the State University of New York at Stonybrook. Substantially all of our
research and development is funded by third parties. We believe this strategy
provides us with a built-in customer base and market. Generally, we retain the
rights to intellectual property developed in our fields of use.
Our Services
We use lasers to either subtract metals from a block of metal (known as,
precision laser materials processing) or to add or deposit metals (known as
laser material deposition processing). The subtractive process uses lasers to
cut away, drill or weld metals to form a part. The additive process uses lasers
to add or build metals on to a surface. Both processes can be used for a wide
variety of commercial applications, including:
o Large parts ("macroscale"), such as jet engine components;
o Handheld parts ("mesoscale"), such as GPS (global positioning
system) antennas and sensors;
o Barely visible or not visible to the human eye size parts
("microscale"), such as medical stents used in angioplasty, gratings
for tunable lasers in telecommunications, and circuitry for next
generation electronics, sensors and medical devices.
Our services can be grouped into three major categories:
1. Precision Laser Materials Processing. Improved performance of lasers
has allowed classic laser materials processing, such as cutting and
welding, to be done at the micro-level. For example, through our
Laser Fare and Mound Laser and Photonics Center, another of our
subsidiaries, we believe we have superior technological capabilities
in this area. Current applications include:
Micro Machining -- Both Laser Fare and Mound provide laser machining
on a micro scale. For example, we currently manufacture
medical devices, such as stents. Stents are sections of small
stainless steel tubing, most of which have been
6
machined away to leave a mesh which can be expanded once the
surgeon has inserted it into an artery. The stent is used to
hold open an artery once an angiogram has been performed.
Macro Machining -- Laser Fare is a leading provider of laser
material processing services to the aerospace, gas turbine,
automotive, and medical industries.
2. Laser Material Deposition Processing. LENS(R) CRADA has developed a
number of methods, many with our involvement, to deposit controlled
amounts of a metal material on a selected surface. Our Laser Fare,
Mound Laser and Photonics Center and Express Pattern subsidiaries
have developed and continue to develop high value manufacturing
services in this area. Examples of laser material deposition
processes, or additive processes, include:
LENS Process -- The LENS(R) CRADA process was developed at Sandia
National Laboratories by a consortium of companies of which we
are a part. As a result, we have an irrevocable, fully-paid
nonexclusive, world-wide license for the technology developed
under this program. Laser Fare has entered into contracts for
macro applications relating to this process. These
applications include depositing metals for the overhaul and
repair of military and high value commercial parts, such as
aerospace parts. We have also begun building mesoscale parts
for such diverse applications as titanium golf club heads and
titanium spinal medical devices. Micro applications include
small fractal antenna fabricated using silver alloys for
handheld GPS (global positioning systems), and other wireless
applications.
Furthermore, the design, manufacture and marketing of wireless
devices is standardized under industry conventions, known as
the Bluetooth conventions, in a manner similar to those set
for traditional telecommunications applications under the
Bellcore standards. We expect to be able to deploy laser
direct write technologies to address wireless components.
Pulsed Laser Deposition -- This is a proprietary process developed
by Mound Laser and Photonics Center to bond one metal to a
different metal using lasers. For example, we can bond very
thin layers of titanium to other metals for high temperature
superconductors (HTS) used in satellite electronics and other
applications.
Rapid Prototyping -- Express Pattern and ATG use a variety of
additive techniques to provide rapid prototyping services to
industrial customers. These services enable customers to
reduce risk in product development by providing fast, low cost
prototypes that allow designs to be tested before large
investments in tooling are made.
3. Laser-related Contract Research and Development. We continue
research and development in both additive and subtractive laser
material processes, as well as GCSEL and diode lasers. We are both a
prime contractor and subcontractor to several projects sponsored by
DARPA. We are subcontractors on three of DARPA's MICE programs.
Other projects include acoustic bandgap research for the U.S. Naval
Underwater Warfare Center ("NUWC") and Electric Boat, as well as
photonic bandgap and high temperature superconductor ("HTS")
research for the U.S. Air Force Research Laboratory ("AFRL").
7
We also have an agreement with the National Center for Manufacturing
Sciences to provide higher quality metal part repairs at a lower
cost than traditional methods under NCMS's Commercial Technologies
for Maintenance Activities Program. This program enables the
cost-effective repair of parts that previously would have been
discarded at significant cost to military and commercial users. NCMS
is a not-for-profit cooperative research consortium and is funded by
the Department of Defense as well as over 175 corporations in the
United States and Canada.
We are also working with researchers at the Photonics Research
Center at the University of Connecticut and at the Ioffe Institute
in St. Petersburg, Russia on grating coupled surface emitting
lasers. The AFRL funds this work.
We intend to continue to use a combination of direct sales to customers,
contract research and development for new and existing customer applications and
early stage prototype assistance to foster our growth and satisfy specific
customer requirements. We will continue to provide these customers with
traditional and advanced manufacturing services to fabricate their components in
the most cost-effective manner.
The Plastics Group
Our Plastics Group provides rapid prototyping services through our Express
Pattern subsidiary, and builds both conventional precision molds and our
proprietary Express Tool molds at our Osley & Whitney subsidiary. We believe the
Express Tool process provides superior thermal management properties over
conventional tooling. Better thermal management allows parts to be ejected from
the molds more quickly than by conventional means, which reduces part distortion
and the cost per part. The process resulted from a research contract in advanced
manufacturing methods at our Laser Fare ATG research facility conducted for
Hasbro. Hasbro retains the rights to the process for the toy and game industry.
We have the intellectual property rights in other fields of use. Once in
production, the process was moved to Osley & Whitney in order to service our
customers. Osley & Whitney is a 50 year-old precision mold builder that services
a blue ribbon list of manufacturers. In addition to their customers, they also
provide manufacturing support to some Laser and Photonic Group customers.
Recent Developments -- Equity Line of Credit
On November 20, 2000 we entered into an equity line of credit agreement
with Cockfield Holdings Limited. The purpose of the equity line of credit is to
provide us with a source of funding for our current activities and for the
development of our current and planned products. The equity line of credit
agreement establishes what is sometimes referred to as an equity drawdown
facility.
Under the equity line of credit agreement, Cockfield has agreed to
purchase up to 3,000,000 shares of our common stock during the 36-month period
beginning February 9, 2001. During this 36-month period, we may request a
drawdown under the equity line of credit by selling shares of our common stock
to Cockfield. The minimum amount we can draw down at any one time is $200,000.
The maximum amount we can draw down at any one time will be determined at the
time of the drawdown request under a formula, but cannot be more than
$5,000,000. We may request a drawdown once every 20 trading days, although we
are under no obligation to request any drawdowns.
In order to exercise our drawdown rights under the equity line of credit
agreement, we must have an effective registration statement on file with the
Securities and Exchange Commission registering the resale of the shares of our
common stock that may be sold to Cockfield under the equity line of credit
agreement. We must also give at least 20 business days advance notice to
Cockfield of the date on which
8
we intend to exercise a particular put right and we must indicate the maximum
number of shares of our common stock that we intend to sell to Cockfield. At our
option, we may also designate a maximum dollar amount of our common stock that
we will sell under the put and/or a minimum purchase price per share at which
Cockfield may purchase shares under the put. The maximum amount may not to
exceed the lesser of a) $5,000,000 or b) fifteen percent (15%) of the weighted
average price of our common stock during the 20 trading days immediately prior
to the put date, multiplied by the total trading volume of our common stock
during the 20 trading days immediately prior to that date.
During the 20 trading days following a drawdown request, we will calculate
the number of shares we will sell to Cockfield and the price per share. The
purchase price per share of common stock will be at a discount to the daily
volume weighted average price of our common stock during the 20 trading days
immediately following the drawdown date. On each of the 20 trading days during
the calculation period, the number of shares to be purchased by Cockfield will
be determined by dividing 1/20th of the drawdown amount by the purchase price on
each trading day. If we designate a minimum purchase price in our drawdown
request and the daily volume weighted average price for our common stock on any
trading day during the 20 trading day calculation period is below the minimum
threshold price, and Cockfield elects not to purchase shares at the minimum
threshold price, then the drawdown amount will be reduced by 1/20th.
For each share of our common stock, Cockfield will pay us 87.5% of the
volume weighted market price for a share of our common stock during the 20-day
trading period following the exercise of a put. The percentage will increase to
90% if we move our principal market to the Nasdaq National Market or to 91% if
we move our principal market to the New York Stock Exchange. It will decrease to
84% if our common stock is delisted from the Nasdaq SmallCap Market. Market
price is defined as the volume weighted average price for our common stock (as
reported by Bloomberg Financial LP using its VAP function) on its principal
market during the pricing period. The pricing period is defined as the 20 day
trading period immediately prior to the day we exercise our put right.
Cockfield will pay for the shares on the 22nd trading day following the
drawdown request. We will receive the purchase price less a brokerage fee
payable to Jesup & Lamont ranging between 4.25% and 4.75% of the aggregate
purchase price, depending on the dollar volume of the transaction. Jesup &
Lamont is the placement agent that introduced Cockfield to us and is a
registered broker-dealer.
At the closing of each drawdown, we will also grant Cockfield warrants to
purchase a number of shares of our common stock equal to 33% of the number of
shares purchased by Cockfield at the closing of the drawdown. These unit
warrants will expire one day after they are granted and will have an exercise
price equal to the weighted average of the purchase price of a share of our
common stock purchased at the closing of each drawdown. The 3,000,000 shares of
common stock available under the equity line of credit will be reduced by the
number of shares issued as a result of the exercise of these unit warrants.
The equity line of credit agreement prevents us from drawing down funds
and issuing the corresponding shares of common stock to Cockfield if the
issuance would result in Cockfield beneficially owning more than 9.9% of our
then outstanding shares of common stock. In addition, the listing requirements
of the Nasdaq SmallCap Market prohibit us from issuing 20% or more of our issued
and outstanding shares of common stock in a single transaction at a price less
than the greater of market value or book value unless we get stockholder
approval. Accordingly, we intend to seek stockholder approval to issue the
shares of our common stock contemplated by the equity line of credit agreement.
As consideration for establishing the equity line of credit, we granted
Cockfield warrants to purchase up to 200,000 shares of our common stock. As
consideration for the services rendered by Jesup & Lamont as placement agent in
connection with the equity line of credit, we granted Jesup & Lamont
9
warrants to purchase up to 100,000 shares of our common stock. These warrants,
covering 300,000 shares of our common stock, are exercisable at any time prior
to November 20, 2003, for $3.135 per share. If the 300,000 warrants are
exercised in full, we would receive gross proceeds of $940,500. Neither
Cockfield nor Jesup & Lamont are obligated to exercise these warrants.
The 3,000,000 shares of our common stock issuable to Cockfield under the
equity line of credit agreement and the 300,000 shares of our common stock
underlying the warrants that were granted to Cockfield and Jesup & Lamont are
covered by a registration statement filed under the Securities Act of 1933 and
may be offered for sale from time to time during the period the registration
statement remains effective. The number of shares covered by that registration
statement represents 95% of our issued and outstanding common stock as of
February 1, 2001. We are obligated to prepare and file amendments and
supplements to that registration statement as are necessary to maintain its
effectiveness until all of those shares are sold or until they can be sold under
an appropriate exemption from registration, whichever is earlier. We agreed to
bear the expenses of registering those shares, including our legal fees, but not
the expenses associated with selling the shares, such as broker discounts and
commissions.
Recent Developments -- New Chief Operating Officer
In October 2000, Thomas Mueller was appointed our chief operating officer
to become effective January 1, 2001. Prior to this appointment, Mr. Mueller was
the president of our Express Pattern subsidiary.
Recent Developments -- Acquisition of MetaTek, Inc.
On December 29, 2000, we acquired all of the outstanding shares of
MetaTek, Inc. in exchange for 76,000 unregistered shares of our common stock in
a transaction that will be accounted for as a pooling of interest. MetaTek is an
Albuquerque, New Mexico based consulting firm specializing in market strategy
and applications for granting coupled surface emitting lasers, and international
applications under Bluetooth wireless conventions. MetaTek's unaudited revenues
for the year ended December 31, 2000 were approximately $345,000.
- --------------------------------------------------------------------------------
We were incorporated under the laws of the state of Delaware on October
14, 1986. On January 7, 1998, we changed our name from Infinite Machines Corp.
to Infinite Group, Inc. Our principal executive offices are located at 2364 Post
Road, Warwick, RI 02886 and our facsimile number is (401) 738-6180. Our
subsidiaries are located in Rhode Island, Massachusetts, New Mexico, Ohio and
Illinois. We maintain sites on the world wide web at www.infinite-group.com,
www.laserfare.com, www.infinitephotonics.com, www.expresstool.com and
www.expresspattern.com. Information contained on any of our websites does not
constitute a part of this prospectus.
- --------------------------------------------------------------------------------
10
RISK FACTORS
A purchase of our common stock is speculative and involves a high degree
of risk. You should carefully consider the risks described below together with
all of the other information included or incorporated by reference in this
prospectus before making an investment decision. The risks and uncertainties
described below are not the only ones we face. If any of the following risks
actually occur, our business, financial condition or operating results could be
harmed. In such case, the trading price of our common stock could decline and
you could lose all or part of your investment.
We have experienced losses in the current and prior years and we anticipate that
we will continue to generate losses for the foreseeable future.
Our operations to date have not been profitable. As of September 30, 2000
we had an accumulated deficit of $19.5 million. We expect to continue operating
at a loss during the current fiscal year and for the foreseeable future. These
losses are primarily attributable to low margins in our injection molding and
laser processing businesses and the significant costs and expenses associated
with manufacturing and marketing many of our other laser technology services as
well as our general and administrative expenses. Other factors that could
adversely affect our operating results include:
o the cost of manufacturing scale-up and production;
o introduction of new products and product enhancements by us or our
competitors;
o changes in applied photonics technologies; and
o changes in general economic conditions.
We cannot assure you that our revenues will increase sufficiently to offset our
operating costs or that, even if they do, that our operations will ever be
profitable.
We are highly leveraged, which increases our operating deficit and makes it
difficult for us to grow.
As of September 30, 2000 we had current liabilities, including trade
payables, of $4.0 million, and long-term liabilities of $5.2 million and a
working capital deficit of $1.3 million. We continue to experience working
capital shortages that materially impair our business operations and growth
strategy. If we continue to incur debt and experience working capital
limitations, our business, operations and financial condition will be materially
adversely affected.
We depend on Cockfield to provide us with capital under the equity line of
credit agreement.
Our immediate financing needs depend on our ability to sell shares of our
common stock to Cockfield under the equity line of credit agreement. There are a
number of factors that could adversely affect our ability to sell shares of our
common stock to Cockfield under the equity line of credit agreement, including:
o Cockfield's ability or willingness to perform its obligations under
the agreement;
o The trading price and volume of our stock. If the market price is
low or the volume is thin, we may not be able to sell a sufficient
number of shares to meet our capital requirements; and
11
o Our ability to sell more than 19.99% of our currently outstanding
shares to Cockfield requires stockholder approval under the Nasdaq
SmallCap Market corporate governance rules. There is no assurance
that we will receive this approval.
Our stockholders may experience significant dilution as a result of stock
issuances under the equity line of credit agreement.
Under the equity line of credit agreement we will sell shares of our
common stock to Cockfield at a price that may be below the market price of our
stock at that time. As a result, these sales will dilute the interests of our
existing stockholders. In addition, as the price of our common stock decreases,
we will be required to issue more shares of our common stock for any given
dollar amount invested by Cockfield. The more shares that are issued under the
equity line of credit, the more our shares will be diluted and the more our
stock price may decrease. This may encourage short sales, which could place
further downward pressure on the price of our common stock. Furthermore, for the
life of any outstanding options and warrants, the holders will have the
opportunity to profit from a rise in the price of the underlying common stock.
When the holders of these options and warrants exercise their rights to acquire
shares of our common stock, the interests of the other stockholders will be
diluted. In addition, the holders of the options and warrants can be expected to
exercise their options and warrants at a time when we would, in all likelihood,
be able to obtain additional capital by an offering of our unissued common stock
on terms more favorable to us than those provided by such options or warrants.
We may require additional financing in the future, which may not be available on
acceptable terms.
Depending on the amount of money we raise under the equity line of credit
agreement with Cockfield and our ability to generate additional revenues, we may
require additional funds to expand our production capability, continue to
develop new applications for our direct write technology and for working capital
and general corporate purposes. At this time, we do not believe that product
sales will reach the level required to sustain our operations and growth plans
in the near term. Therefore, we are actively pursuing additional financing
alternatives. However, other than the equity line of credit with Cockfield, we
do not have any commitments for additional financing and we cannot assure you
that any additional financing will be available or, if available, will be
offered on acceptable terms. The equity line of credit agreement limits our
ability to sell our securities to third parties at a discount to the market
price during its term. Accordingly, if we need additional capital but are unable
to draw down under the equity line of credit agreement for any reason, our
access to capital may be limited. In addition, any additional equity financing
may be dilutive to stockholders, and debt financings, if available, may involve
restrictive covenants that further limit our ability to make decisions that we
believe will be in our best interests. In the event we cannot obtain additional
financing on terms acceptable to us when required, our operations will be
materially adversely affected and we will have to cease or substantially reduce
operations.
Some of our products and services are at an early stage of development and may
not achieve market acceptance.
Currently, our primary focus is to develop new commercial applications for
GCSEL, diode laser and laser driven direct write technologies. Many of the
benefits of GCSEL, diode laser and laser driven direct write technologies are
not widely known. Therefore, we anticipate that we will need to educate our
target markets to generate demand for our services and, as a result of market
feedback, we may be required to further refine these services. In order to
persuade potential customers to purchase our services, we will need to overcome
industry resistance to, and suspicion of, new technologies. In addition,
developing new applications for these technologies and other new technologies
will require significant further research, development, testing and marketing
prior to commercialization. We cannot
12
assure you that commercial applications of these technologies can be
successfully developed, marketed or produced.
Some of our current products and services have not been commercially successful.
Our laser materials processing and mold building products and services do
not generate a significant amount of revenue, even though they have been
available for some time. In addition, most of our revenue from these businesses
is generated from a limited number of customers. We cannot assure you that these
customers will continue to purchase these products and services or that we will
be able to expand the market for these products and services. Our resources
available for sales and marketing activities are limited. Therefore, any
material delay, retooling, cancellation or reduction in orders from the
customers who purchase these products and services could have a material adverse
affect on our business, operations and financial condition.
We have limited marketing and sales capabilities and must make sales in
fragmented markets.
Our future success depends, to a great extent, on our ability to
successfully market our products and services. We currently have limited sales
and marketing capabilities and experience and we will need to hire qualified
sales and marketing personnel, develop additional sales and marketing programs
and establish sales distribution channels in order to achieve and sustain
commercial sales of our products. Qualified sales and marketing personnel in
this area are in short supply and we cannot assure you that we will be able to
hire them. In addition, our ability to successfully market our products and
services is further complicated by the fact that our principal markets, laser
photonics, telecommunications, aerospace and medical components, are highly
fragmented. Consequently, we will need to identify and successfully target
particular market segments in which we believe we will have the most success.
These efforts will require a substantial, but unknown, amount of effort and
resources. We cannot assure you that any marketing and sales efforts undertaken
by us will be successful or will result in any significant product sales.
We depend on the aerospace, laser photonic and medical device industries, which
continually produce technologically advanced products.
A majority of our sales are to companies in the aerospace, laser photonic,
telecommunications and medical device industries, which are subject to rapid
technological change and product obsolescence. If our customers are unable to
create products that keep pace with the changing technological environment and
market demand, their products could become obsolete and the demand for our
services could decline significantly. If we are unable to offer cost-effective,
quick-response manufacturing services to customers, demand for our services will
also decline. This would have a material adverse affect on our business,
operations and financial condition.
Our industry is intensely competitive, which may adversely affect our operations
and financial results.
All our markets are intensely competitive and numerous companies offer
conventional and laser driven products and services that compete with our
products and services. We anticipate that competition for our products and
services will continue to increase. Most of our competitors have substantially
greater capital resources, research and development staffs, manufacturing
capabilities, sales and marketing resources, facilities and experience. These
companies, or others, could undertake extensive research and development in
laser technology and related fields that could result in technological changes.
Many of these companies also are primary customers for various components, and
therefore have significant control over certain markets that we have targeted.
In addition, we may not be able to offer
13
prices as low as some of our competitors because those competitors may have
lower cost structures as a result of their geographic location or the services
they provide. Our inability to provide comparable or better products and
services at a lower cost than our competitors could cause our net sales to
decline. We cannot assure you that our competitors will not succeed in
developing technologies in these fields which will enable them to offer laser
services more advanced and less costly than those we offer or which could render
our technologies obsolete.
Our products and services are subject to industry standards, which increases
their cost and could delay or bar their commercial acceptance.
Since some of our products and services are used in the telecommunications
industry, they must comply with the Bellcore Testing standards for traditional
equipment and/or Bluetooth standards for wireless devices. These standards
govern the design, manufacture and marketing of these items. If we fail to
comply with these standards, we will not be able to sell our products. We may
encounter significant delays or incur additional costs in our efforts to comply
with these industry standards.
We depend on our relationship with third parties to develop and commercialize
new products.
Our strategy for research and development and for the commercialization of
our products contemplates a continuing relationship with various publicly and
privately funded consortia and our existing relationships will continue with
strategic partners, OEMs, licensees and others. We depend on these associations
and relationships not only to underwrite our research and development efforts,
but also for product testing and to create markets for our products and
services. We cannot assure you that our existing relationships will continue or
the extent to which the parties to such arrangements will continue to allocate
time of resources to these strategic alliances. Similarly, we cannot assure you
that we will be able to enter into new arrangements in the future. In addition,
we cannot assure you that such agreements will progress to a production phase
or, if production commences, that we will receive significant revenues as a
result of these relationships. We cannot assure you that these parties, or any
future partners, will perform their obligations as expected or that any revenue
will be derived from such arrangements.
We have only limited manufacturing capabilities and our inability to continually
manufacture products on a cost-effective basis would harm our business.
We have limited production facilities and limited experience in
manufacturing our product offerings. To the extent any of our existing or future
products must be produced in commercially reasonable quantities, we will have to
either develop that expertise quickly or outsource that function. Developing
manufacturing capability is an expensive and time-consuming endeavor and we do
not have the resources that are required for a full-scale manufacturing
capability. Therefore, in all likelihood we will have to engage a third party to
manufacture our products for us. In that event, we will depend on the
manufacturer to produce high-quality products based on our specifications, on
time and within budget. If we are unable to manufacture products in sufficient
quantities and in a timely manner to meet customer demand ourselves or by
others, our business, financial condition and results of operations will be
materially adversely affected.
We depend on our intellectual property rights to provide us with a competitive
advantage.
Our ability to compete successfully depends, in part, on our ability to
protect our products and technologies under United States and foreign patent
laws, to preserve trade secrets and other proprietary information and
technologies, and to operate without infringing the proprietary rights of
others. We cannot assure you that patent applications relating to our products
or potential products will result in patents being issued, that any issued
patents will afford adequate protection or not be challenged,
14
invalidated, infringed or circumvented, or that any rights granted will give us
a competitive advantage. Furthermore, we cannot assure you that others have not
independently developed, or will not independently develop, similar products
and/or technologies, duplicate any of our product or technologies, or, if
patents are issued to, or licensed by, us, design around such patents. We cannot
assure you that patents owned or licensed and issued in one jurisdiction will
also be issued in any other jurisdiction. In addition, we cannot assure you that
we can adequately protect our proprietary technology and processes that we
maintain as trade secrets. If we are unable to develop and adequately protect
our proprietary technology and other assets, our business, financial condition
and results of operations will be materially adversely affected.
We depend on the continued services of our key personnel.
Our future success depends, in part, on the continuing efforts of our
senior executive officers, Clifford G. Brockmyre II, Thomas Mueller, J. Terence
Feeley and Bruce J. Garreau, who conceived our strategic plan and who are
responsible for executing that plan. The loss of any of these key employees may
adversely affect our business. At this time we do not have any term "key man"
insurance on any of these executives other than a $1.7 million policy on
Clifford G. Brockmyre II. If we lose the services of any of these senior
executives, our business, operations and financial condition could be materially
adversely affected.
We may have difficulties in managing our growth.
Our future growth depends, in part, on our ability to implement and expand
our financial control systems and to expand, train and manage our employee base
and provide support to an expanded customer base. If we cannot manage growth
effectively, it could have material adverse effect on our results of operations,
business and financial condition. In 1999 we made two acquisitions and opened a
new facility in Illinois. Acquisitions and expansion involve substantial
infrastructure and working capital costs. We cannot assure you that we will be
able to integrate our acquisitions and expansions efficiently. Similarly, we
cannot assure you that we will continue to expand or that any expansion will
enhance our profitability. If we do not achieve sufficient revenue growth to
offset increased expenses associated with our expansion, our results will be
adversely affected.
We must attract, hire and retain qualified personnel.
As we continue to develop new products and as our business grows,
significant demands will be placed on our managerial, technical, financial and
other resources. One of the keys to our future success will be our ability to
attract, hire and retain highly qualified engineering, marketing, sales and
administrative personnel. Competition for qualified personnel in these areas is
intense and we will be competing for their services with companies that have
substantially greater resources than we do. We cannot assure you that we will be
able to identify, attract and retain employees with skills and experience
necessary and relevant to the future operations of our business. Our inability
to retain or attract qualified personnel in these areas could have a material
adverse effect on our business and results of operations.
We face potential product liability claims.
The sale of our telecommunications, aerospace and medical products and
services will involve the inherent risk of product liability claims by others.
We maintain product liability insurance coverage. However, we cannot assure that
the amount and scope of our existing coverage is adequate to protect us in the
event that a product liability claim is successfully asserted. Moreover, we
cannot assure you that we will continue to maintain the coverage we currently
have. Product liability insurance is expensive, subject to various coverage
exclusions and may not always be obtainable on terms acceptable to us.
15
Our stock price is volatile and could be further affected by events not within
our control.
The trading price of our common stock has been volatile and will continue
to be subject to:
o Volatility in the trading markets generally;
o Significant fluctuations in our quarterly operating results;
o Announcements regarding our business or the business of our
competitors;
o Changes in prices of our or our competitors' products and services;
o Changes in product mix; and
o Changes in revenue and revenue growth rates for us as a whole or for
geographic areas, and other events or factors.
Statements or changes in opinions, ratings or earnings estimates made by
brokerage firms or industry analysts relating to the markets in which we operate
or expect to operate could also have an adverse effect on the market price of
our common stock. In addition, the stock market as a whole has from time to time
experienced extreme price and volume fluctuations which have particularly
affected the market price for the securities of many small cap companies and
which often have been unrelated to the operating performance of these companies.
The price of our common stock may be adversely affected by the possible issuance
of shares of our common stock under the equity line of credit agreement and as a
result of the exercise of outstanding warrants and options.
In addition to the 446,500 shares of our common stock covered by this
prospectus, we have previously registered 3,300,000 shares of common stock to
the equity line of credit agreement and all of the shares of our common stock
reserved for issuance under our stock option plan. To date, we have granted
options covering 980,991 of these shares. In addition, we have issued warrants
covering 709,975 shares of common stock. We have agreed with certain of these
holders to register the shares underlying their warrants. As a result of the
actual or potential sale of these shares into the market, our common stock price
may decrease. In that event not only would you lose a portion of your
investment, but we would probably find it more difficult to obtain additional
financing.
Concentration of ownership
As of February 1, 2001, our chief executive officer, Clifford G. Brockmyre
II, is our largest stockholder, owning approximately 24% of our issued and
outstanding shares of our common stock. Assuming all of the shares of our common
stock covered by this prospectus are issued, Mr. Brockmyre will own 12%. In
either event, Mr. Brockmyre, as a result, effectively controls all our affairs,
including the election of directors and any proposals regarding a sale of the
Company or its assets or a merger.
Some provisions in our charter documents and bylaws may have anti-takeover
effects.
Our certificate of incorporation and bylaws contain provisions that may
make it more difficult for a third party to acquire us, with the result that it
may deter potential suitors. For example, our board of directors is authorized,
without action of the stockholders, to issue authorized but unissued common
stock
16
and preferred stock. The existence of undesignated preferred stock and
authorized but unissued common stock enables us to discourage or to make it more
difficult to obtain control of us by means of a merger, tender offer, proxy
contest or otherwise.
Absence of dividends to shareholders.
We have never declared a dividend on our common stock. We do not
anticipate paying dividends on the common stock in the foreseeable future. We
anticipate that earnings, if any, will be reinvested in the expansion of our
business.
We have agreed to limitations on the potential liability of our directors.
Our certificate of incorporation provides that, in general, directors will
not be personally liable for monetary damages to the company or our stockholders
for a breach of fiduciary duty. Although this limitation of liability does not
affect the availability of equitable remedies such as injunctive relief or
rescission, the presence of these provisions in the certificate of incorporation
could prevent us from recovering monetary damages.
We must maintain compliance with certain criteria in order to maintain listing
of our shares on the Nasdaq market.
Our common stock is currently traded on the Nasdaq SmallCap Market. In
order to maintain this listing, we are required to meet certain requirements
relating to our stock price and our net tangible assets. If we fail to meet
these requirements, our stock could be delisted. On April 18, 2000, we received
a letter from Nasdaq that we failed to satisfy the minimum net tangible asset
listing requirements for the SmallCap Market. As a result of private placements
transactions consummated after September 30, 2000, we believe we are currently
in compliance with the net tangible asset requirement. However, we cannot assure
you that Nasdaq will agree or that we will continue to satisfy the Nasdaq
SmallCap Market listing requirements. If our stock is delisted, it will trade on
the OTC Bulletin Board or in the "pink sheets" maintained by the National
Quotation Bureau Incorporated. As a consequence of such delisting, an investor
could find it more difficult to dispose of or to obtain accurate quotations as
to the market value of our securities. Among other consequences, delisting from
Nasdaq may cause a decline in the stock price and difficulty in obtaining future
financing.
The liquidity of our stock could be severely reduced if it becomes classified as
"penny stock".
The Securities and Exchange Commission has adopted regulations which
generally define a "penny stock" to be any non-Nasdaq equity security that has a
market price (as therein defined) of less than $5.00 per share or with an
exercise price of less than $5.00 per share. If our securities were subject to
the existing rules on penny stocks, the market liquidity for our securities
could be severely adversely affected. For any transaction involving a penny
stock, unless exempt, the rules require substantial additional disclosure
obligations and sales practice obligations on broker-dealers where the sale is
to persons other than established customers and accredited investors (generally,
those persons with assets in excess of $1,000,000 or annual income exceeding
$200,000, or $300,000 together with their spouse). For transactions covered by
these rules, the broker-dealer must make a special suitability determination for
the purchase of the common stock and have received the purchaser's written
consent to the transaction prior to the purchase. Additionally, for any
transaction involving a penny stock, unless exempt, the rules require the
delivery, prior to the transaction, of a risk disclosure document mandated by
the Commission relating to the penny stock market. The broker-dealer also must
disclose the commissions payable to both the broker-dealer and the registered
representative, current quotations for the securities and, if the broker-dealer
is the sole market-maker, the broker-dealer must disclose this fact and the
broker-dealer's
17
presumed control over the market. Finally, monthly statements must be sent
disclosing recent price information for the penny stock held in the account and
information on the limited market in penny stocks. Consequently, the "penny
stock" rules may restrict the ability of broker-dealers to sell the common stock
and accordingly the market for our common stock.
USE OF PROCEEDS
All of the shares of our common stock offered by this prospectus are being
registered for the account of the selling stockholders. We will not receive any
of the proceeds from the sale of these shares. However, we will receive the
proceeds from the exercise of the warrants covering the 154,300 shares of common
stock covered by this prospectus to the extent those warrants are exercised.
These proceeds would be approximately $300,000 if all the warrants are
exercised. In addition, this prospectus also covers 31,250 shares of common
stock that a selling stockholder is obligated to purchase from us on May 26,
2001 for $62,500. We expect to use substantially all the net proceeds from the
exercise of the warrants and the sale of the shares for general corporate
purposes, including reach and development, expansion of sales and marketing
activities and working capital. We will retain broad discretion in the
allocation of those net proceeds.
18
SELLING STOCKHOLDERS
The following table sets forth the name and the number of shares of our
common stock beneficially owned by each selling stockholder as of February 1,
2001 and as adjusted to reflect the sale of the shares offered by this
prospectus, by each selling stockholder. Except as otherwise indicated, the
persons listed below have sole voting and investment power with respect to all
shares of common stock owned by them including those shares not yet issued. In
addition, unless otherwise indicated, none of the selling stockholders has had a
material relationship with us or any of our affiliates within the past three
years. All information with respect to beneficial ownership has been furnished
to us by the respective stockholder.
Shares Shares
Beneficially Beneficially
Owned Prior to Owned After the
Offering(1) Offering
---------------------- -------------------
Name of Beneficial Shares
Owner Number Percent Offered Number Percent
- ----------------------- ---------- --------- ----------- -------- --------
Neptune Capital, Inc. (2) 300,000 8.39% 300,000 -- --
6119 Camino-de-la-Costa
La Jolla, CA 92037
Upstate Holdings, LLC (3) 100,000 2.81% 100,000 -- --
968 Emerald Street, Suite 262
San Diego, CA 92109
Dr. Peter Dewhurst (4) 19,400* * 19,400 -- --
376 Dug Way Bridge Road
West Kingston, RI 02892
Dr. Brent Stucker (4) 19,400* * 19,400 -- --
53 Punchbowl Trail
Kingston, RI 02892
James P. Tiernan (5) 7,700* * 7,700 -- --
115 Buena Vista Drive
North Kingstown, RI 02892
- ----------------------
* Less than 1%.
(1) Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission. In computing the number of shares
beneficially owned by a person and the percentage ownership of that
person, shares of common stock underlying options and warrants held by
that person that are currently exercisable or exercisable within 60 days
of February 1, 2001 are deemed outstanding. These shares, however, are not
deemed outstanding for the purpose of computing the percentage ownership
of any other person.
(2) Includes 50,000 shares subject to currently exercisable warrants
(exercisable at $1.625 per share through May 31, 2005) and 31,250 shares
issuable on May 26, 2001 pursuant to a subscription agreement. The
purchase price for those shares is $2 per share, or $62,500 in the
aggregate.
(3) All shares are covered by currently exercisable warrants, exercisable at
$2.00 per share through May 31, 2005.
(4) Includes 1,800 shares covered by currently exercisable options,
exercisable at $3.95 per share through October 13, 2003.
(5) Includes 700 shares covered by currently exercisable options, exercisable
at $3.95 per share through October 13, 2003.
19
PLAN OF DISTRIBUTION
The selling stockholders and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of their shares
of common stock covered by this prospectus on any stock exchange, market or
trading facility on which the shares are traded or in private transactions.
These sales may be at fixed or negotiated prices. The selling stockholders may
use any one or more of the following methods when selling shares:
o ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers;
o block trades in which the broker-dealer will attempt to sell the
shares as agent but may position and resell a portion of the block
as principal to facilitate the transaction;
o purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;
o an exchange distribution in accordance with the rules of the
applicable exchange;
o privately negotiated transactions;
o short sales;
o broker-dealers may agree with the selling stockholders to sell a
specified number of such shares at a stipulated price per share;
o a combination of any such methods of sale; and
o any other method permitted pursuant to applicable law.
The selling stockholders may also sell shares under Rule 144 under the
Securities Act, if available, rather than under this prospectus.
The selling stockholders may also engage in short sales against the box,
puts and calls and other transactions in our securities or derivatives of our
securities and may sell or deliver shares in connection with these trades. The
selling stockholders may pledge their shares to their brokers under the margin
provisions of customer agreements. If a selling stockholder defaults on a margin
loan, the broker may, from time to time, offer and sell the pledged shares.
Broker-dealers engaged by the selling stockholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as
agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated. The selling stockholders do not expect these commissions and
discounts to exceed what is customary in the types of transactions involved.
The selling stockholders and any broker-dealers or agents that are
involved in selling the shares may be deemed to be "underwriters" within the
meaning of the Securities Act in connection with such sales. In such event, any
commissions received by such broker-dealers or agents and any profit on the
resale of the shares purchased by them may be deemed to be underwriting
commissions or discounts under the Securities Act.
20
We will pay all of the expenses relating to the registration of the shares
covered by this prospectus except for selling commissions. These expenses are
estimated at $22,000.00.
LEGAL MATTERS
The validity of the common stock offered hereby will be passed upon by
Morse, Zelnick, Rose & Lander, LLP. Members of Morse, Zelnick, Rose & Lander,
LLP own options to purchase 65,000 shares of our common stock.
EXPERTS
The financial statements of Infinite Group Inc. as of December 31, 1999,
and for each of the years in the three-year period ended December 31, 1999, are
incorporated by reference in this prospectus and in the registration statement
in reliance upon the report of Freed Maxick Sachs & Murphy, P.C., independent
certified public accountants, incorporated by reference herein, upon the
authority of said firm as experts in accounting and auditing.
21
PROSPECTUS
INFINITE GROUP, INC.
446,500 Shares
Common Stock
Dated: ______________________, 2001
22
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The fees and expenses we incurred in connection with the offering are
payable by us and, other than registration, filing and listing fees, are
estimated as follows:
SEC registration fee .................................... $ 336.00
Accounting fees and expenses ............................ 2,500.00*
Legal fees and expenses ................................. 15,000.00*
Printing costs .......................................... 1,000.00*
Miscellaneous expenses .................................. 3,164.00*
-------------
Total .............................................. $ 22,000.00*
=============
- -----------------------
* To be provided by amendment.
Item 15. Indemnification of Officers and Directors
Our Certificate of Incorporation provides that the indemnification
provisions of Sections 102(b)(7) and 145 of the Delaware General Corporation Law
shall be utilized to the fullest extent possible. Further, the Certificate of
Incorporation contains provisions to eliminate the liability of our directors to
Infinite or its stockholders to the fullest extent permitted by Section
102(b)(7) of the Delaware General Corporation Law, as amended from time to time.
Section 145 of the Delaware General Corporation Law provides that a
corporation may indemnify directors and officers as well as other employees and
individuals against expenses (including attorneys' fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred by such person in
connection with any threatened, pending or completed actions, suits or
proceedings in which such person is made a party by reason of such person being
or having been a director, officer, employee or agent of the corporation. The
Delaware General Corporation Law provides that Section 145 is not exclusive of
other rights to which those seeking indemnification may be entitled under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise.
Section 102(b)(7) of the Delaware General Corporation Law permits a
corporation to provide in its certificate of incorporation that a director of
the corporation shall not be personally liable to the corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director,
except for liability (i) for any breach of the director's duty of loyalty to the
corporation or its stockholders, (ii) for acts or omissions not in good faith or
which involve intentional misconduct or a knowing violation of law, (iii) for
unlawful payments of dividends or unlawful stock repurchases, redemptions or
other distributions, or (iv) for any transaction from which the director derived
an improper personal benefit. Our Certificate of Incorporation provides for such
limitation of liability.
Insofar as indemnification for liabilities arising under the Securities
Act of 1933, as amended, is permitted for our directors, officers or controlling
persons, pursuant to the above mentioned statutes or otherwise, we understand
that the Securities and Exchange Commission is of the opinion that such
II-1
indemnification may contravene federal public policy, as expressed in said Act,
and therefore, may be unenforceable. Accordingly, in the event that a claim for
such indemnification is asserted by any of our directors, officers or
controlling persons, and the Commission is still of the same opinion, we (except
insofar as such claim seeks reimbursement from us of expenses paid or incurred
by a director, officer of controlling person in successful defense of any
action, suit or proceeding) will, unless the matter has theretofore been
adjudicated by precedent deemed by our counsel to be controlling, submit to a
court of appropriate jurisdiction the question whether or not indemnification by
it is against public policy as expressed in the Act and will be governed by the
final adjudication of such issue.
At present, there is no pending litigation or proceeding involving any of
our directors, officers or employees as to which indemnification is sought, nor
are we aware of any threatened litigation or proceeding that may result in
claims for indemnification.
Item 16. Exhibits
The following exhibits are filed with this Registration Statement:
Exhibit
No. Description
- ---------- -----------------------------------------------------------------
2.1 Equity Line of Credit Agreement dated November 20, 2000, between
Registrant and Cockfield Holdings Limited*
2.2 Registration Rights Agreement dated November 20, 2000, between
Registrant and Cockfield Holdings Limited*
2.3 Escrow Agreement dated as of November 20, 2000, among Registrant,
Cockfield Holdings Limited and Epstein Becker & Green, P.C.*
2.4 Form of Stock Purchase Warrant dated November 20, 2000, issued to
each of Cockfield Holdings Limited and Jesup & Lamont Securities
Corporation*
5.1 Opinion and consent of Morse, Zelnick, Rose & Lander, LLP
10.2 Form of Stock Option Agreement. (Filed as Exhibit 10M to the
Registrant's Annual Report on Form 10-KSB for the year ended June
30, 1995 (Commission File No. 0-13789), and incorporated herein
by reference.)
10.1 Lease for facilities at 2364 Post Road, Warwick, RI 02886. (Filed
as Exhibit 10B to the Registrant's Annual Report on Form 10-KSB
for the year ended June 30, 1995 (Commission File No. 0-13789),
and incorporated herein by reference.)
10.3 Employment Agreement with Bruce J. Garreau. (Filed as Exhibit
10.20 to the Registrant's Annual Report on Form 10-KSB for the
year ended December 31, 1999 (Commission File No. 000-13789), and
incorporated herein by reference.)
10.4 Employment Agreement with J. Terence Feeley. (Filed as Exhibit
10.19 to the Registrant's Annual Report on Form 10-KSB for the
year ended December 31, 1999 (Commission File No. 000-13789), and
incorporated herein by reference.)
II-2
Exhibit
No. Description
- ---------- -----------------------------------------------------------------
10.5 Employment Agreement with Thomas J. O'Connor. (Filed as Exhibit
10.24 to the Registrant's Annual Report on Form 10-K for the year
ended December 31, 1999 (Commission File No. 000-13789), and
incorporated herein by reference.)
10.6 Employment Agreement with Clifford G. Brockmyre II (Filed as
Exhibit 10.14 to the Registrant's Annual Report on form 10-KSB
for the year ended December 31, 1997)
10.7 Amendment to Employment Agreement with Clifford G. Brockmyre II
(Filed as Exhibit 10.7 to Registration Statement No. 333-51768
filed December 11, 2000 and incorporated herein by reference)
23.1 Consent of Freed Maxick Sachs & Murphy, P.C.
23.2 Consent of Morse, Zelnick, Rose & Lander, LLP (included in
Exhibit 5.1)
24 Power of Attorney (reference is made to the signature pages to
the Registration Statement)
27 Financial Data Schedule
- ------------------------
* Filed as a corresponding Exhibit to Registration Statement No. 333-51768
filed December 11, 2000 and incorporated herein by reference.
Item 17. Undertakings
The undersigned registrant hereby undertakes:
(1) to file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:
(i) to include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) to reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the
information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of
prospectus frilled with the Commission pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price
represent no more than 20% change in the maximum aggregate
offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement; and
(iii) to include any material information with respect to the plan
of distribution not previously disclosed in the registration
statement or any material change to such information in the
registration statement;
II-3
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply
if the information required to be included in a post-effective amendment by
those paragraphs is contained in periodic reports filed with or furnished to the
Commission by the Registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934, that are incorporated by reference in this
Registration Statement.
(2) that, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof; and
(3) to remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of this offering.
(b) The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in this Registration Statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise,
the Registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Securities Act of 1933 and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the
payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Registrant will, unless
in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act of 1933 and will be governed by the final adjudication of such
issue.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Warwick, State of Rhode Island and Providence
Plantations on this 14th day of February, 2001.
INFINITE GROUP INC.
By: /s/ Clifford G. Brockmyre, II
--------------------------------
Clifford G. Brockmyre II,
President, Chief Executive Officer
And Chairman of the Board
POWER OF ATTORNEY
KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Clifford G. Brockmyre II as his
true and lawful attorney-in-fact and agent, with full power of substitution, for
him and in his name, place and stead, in any and all capacities, to sign any or
all amendments or post-effective amendments to this Registration Statement, and
to file the same, with all exhibits thereto, which amendments may make such
changes in this Registration Statement as such agent deems appropriate, and to
file any new registration statement (and any post-effective amendment thereto)
which registers additional securities of the same class and for the same
offering as this Registration Statement in accordance with Rule 462(b) under the
Securities Act (each, a "462(b) Registration Statement"), and the Registrant and
each such person hereby appoints each such Agent as attorney-in-fact to execute
in the name and on behalf of the Registrant and each such person, individually
and in each capacity stated below, any such amendments to this registration
statement and any such 462(b) Registration Statements, and other documents in
connection therewith, with the Commission.
Pursuant to the requirements of the Securities Act of 1933, as amended, this
Registration Statement has been signed by the following persons in the
capacities indicated on February 14, 2001.
Signature Title
---------------------------------------
/s/ Clifford G. Brockmyre II President, Chief Executive Officer and
- ------------------------------------ Chairman of the Board (Principal
Clifford G. Brockmyre II Executive Officer)
/s/ Bruce J. Garreau Chief Financial Officer
- ------------------------------------ (Principal Financial and Accounting
Bruce J. Garreau Officer)
/s/ J. Terence Feeley Director
- ------------------------------------
J. Terence Feeley
/s/ Brian Q. Corridan Director
- ------------------------------------
Brian Q. Corridan
/s/ William G. Lyons III Director
- ------------------------------------
William G. Lyons III
/s/ Michael S. Smith Director
- ------------------------------------
Michael S. Smith
II-5